In some embodiments, the formulation or composition has a viscosity between about 10 cP to about 10,000 cP
The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it. Microdosing has been used for tolerability testing, metabolic-marker support, step-down protocols, and maintenance, not for proven long-term obesity outcomes
Some users notice warming sensations near injection sites, possibly related to increased local blood flow from nitric oxide effects
Therapeutic doses used in research rarely cause clinically significant changes, but those with hypotension or taking blood pressure medications should monitor carefully
[DOI] [PMC free article] [PubMed] [Google Scholar] 134.Tepes M., Gojkovic S., Krezic I., Zizek H., Vranes H., Madzar Z., Santak G., Batelja L., Milavic M., Sikiric S., et al